Association of Genetic Polymorphisms With Atrial Fibrosis and Thrombogenic Substrate in Patients With Non-valvular Atrial Fibrillation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

225 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-07-01

Study Completion Date

2019-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Atrial fibrillation (AF) is the most frequently encountered cardiac arrhythmia. Emerging data suggests that common genetic variants are associated with the development of AF. The main feature of the structural remodelling in AF is atrial fibrosis and is considered the substrate for AF perpetuation. Genome-wide association studies suggest that AF-susceptibility variants may modulate atrial fibrosis. However, the association between atrial fibrosis and genetic polymorphisms in humans has not yet been specifically investigated. In this study, we plan to investigate the relationship between genetic polymorphisms, atrial fibrosis and other components of thrombogenic substrate in patients with non-valvular AF. Primary objectives of this study are to assess associations between (i) polymorphic genetic variants and atrial fibrosis (detected by magnetic resonance imaging), (ii) polymorphic genetic variants and components of thrombogenic substrate (inflammation, endothelial function, prothrombotic state, atrial functions).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of Genetic Risk of Atrial Fibrillation

NCT00412438

Atrial Fibrillation

UNKNOWN

Atrial Fibrillation Incidence, Risk Factors and Genetics

NCT00021905

Atrial Fibrillation Cardiovascular Diseases Heart Diseases +3 more

COMPLETED

Left Atrial Low vOltage Zone, GenetIC Markers and Outcomes in Patients After Atrial Fibrillation abLation

NCT02074826

Atrial Fibrillation

UNKNOWN

A Cross-sectional Study for the Determination of the Prevalence of Non-valvular Atrial Fibrillation Among Patients Diagnosed With Hypertension

NCT02585076

Hypertension Atrial Fibrillation

COMPLETED

Genetic Risk-Based Atrial Fibrillation Screening (GeneAF Study)

NCT04932798

Genetic Predisposition Atrial Fibrillation

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Atrial fibrillation (AF) is the most frequently encountered cardiac arrhythmia. Emerging data suggests that common genetic variants are associated with the development of AF. The main feature of the structural remodelling in AF is atrial fibrosis and is considered the substrate for AF perpetuation. Genome-wide association studies suggest that AF-susceptibility variants may modulate atrial fibrosis. However, the association between atrial fibrosis and genetic polymorphisms in humans has not yet been specifically investigated. In this study, we plan to investigate the relationship between genetic polymorphisms, atrial fibrosis and other components of thrombogenic substrate in patients with non-valvular AF. Primary objectives of this study are to assess associations between (i) polymorphic genetic variants and atrial fibrosis (detected by magnetic resonance imaging), (ii) polymorphic genetic variants and components of thrombogenic substrate (inflammation, endothelial function, prothrombotic state, atrial functions). Patients are planned to be recruited from four major cardiology departments: Memorial Ankara Hospital, Ministry of Health Subspecialty Training Hospital of Turkey, Ufuk University and Gazi University hospitals. Key variables that will be recorded include the clinical, contrast-enhanced MRI, biomarkers, echocardiographic and assessment of endothelial function. All statistical analyses will be conducted using Stata version 11.0 (StataCorp, College Station, TX). Univariate and multivariate regression models will be used to determine the odds ratio of each variable to assess the association of the clinical and laboratory parameters, and genotype profiles with the presence of LA fibrosis. Furthermore, data mining methods like support vector machines and/or random forests are planned to be used for detecting the impact of each potential predictor on the risk of LA fibrosis. Additionally, to determine the effect of different alleles of the identified risk SNPs, 2-way and 3-way multi dimensionality reduction (MDR) analysis will be performed. Bioinformatics investigations to determine SNP-SNP, SNP-gene and SNP-Phenotype interactions will be performed by combined p-value and biological network analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Thrombosis Stroke Genetic Predisposition Heart Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biomarkers, Cardiac Magnetic Resonance Imaging, Echocardiography, Flow Mediated Dilatation, Genetic Analysis

Key variables that will be recorded include the following:

* Clinical

* Age
* Gender
* BMI
* Diabetes Mellitus
* Hypertension
* Heart Failure
* Ischemic Stroke / TIA
* Thromboembolism
* Coronary Artery Disease
* Peripheral Arterial Disease
* Glomerular Filtration Rate
* Contrast-enhanced MRI

o Presence and extent of atrial fibrosis
* Biomarkers

* IL-6
* CRP
* D-dimer
* Fibrinogen
* Transthoracic Echocardiography

* LA Volume Index (LAVI)
* LA Strain, Global
* LA Strain rate, Positive peak, Global
* LA Strain rate, early negative peak, Global
* LA Strain rate, late negative peak, Global
* LA Emptying Fraction (LAEF)
* LVH
* LVEF
* Endothelial function o FMD

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \>18 years
* Documented AF
* Paroxysmal and persistent AF

Exclusion Criteria

* Patients with infectious or non-infectious inflammatory disease
* Patients with structural heart disease
* Acute coronary syndrome
* Severe liver and kidney dysfunction
* Cancer
* Immune disorders
* Surgery and stroke within six months

Minimum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No